Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
This article was originally published in The Pink Sheet Daily
In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.
You may also be interested in...
Meta-analysis published in JAMA suggests registry-based studies could be alternative to large cardiovascular outcomes trials.
Even though both components are already marketed, firm might have to do another study for fixed-dose combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin.
Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.